Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Vir Biotechnology will present expanded Phase 2 SOLSTICE data for elebsiran and tobevibart in chronic hepatitis delta at AASLD's The Liver Meeting 2026 in Denver, November 5-9. Two oral presentations are scheduled for November 8: one covering HDV RNA response patterns through Week 96 and another a translational sub-study on intrahepatic NK cell remodelling.
Key figures
- Drug Name
- elebsiran + tobevibart
- Phase Of Trial
- Phase 2
- Trial Name
- SOLSTICE
- Conference
- AASLD The Liver Meeting 2026
- Presentation Date
- November 8, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.